Axsome Therapeutics, Inc. (AXSM) Stock: Price, Forecast & Analyst Target
Axsome Therapeutics, Inc. (AXSM) — MoonshotScore 34/100 (Weak band), calculated Nov 18, 2026. Price $135.68 (+1.25%), as of the Nov 19, 2026 trading session; market cap $7.14B. Expected results Feb 22, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 22.75× (cash as of Sep 30, 2026) · expected results Feb 22, 2027
Axsome Therapeutics, Inc. · AXSM · NASDAQ · Healthcare · Biotechnology
Research dated 2026-09-13: Axsome Therapeutics is a commercial biopharmaceutical company selling central nervous system medicines while advancing a broad clinical pipeline across depression, migraine, sleep disorders, pain and neuropsychiatric conditions. The case depends on whether product revenue can outgrow the commercial and research spending that still keeps the business unprofitable and usually cash consumptive.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Axsome Therapeutics (AXSM)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
A full valuation, though the balance sheet is only middling. The score also carries a risk penalty for losses on top of negative retained earnings. Business Quality: Solid; Financial Safety: Okay; Valuation: Full; Growth Durability: Growing; Momentum: Quiet.
- quarterly revenue $171M (Q3 FY2025, quarter ended Sep 2025)
- EPS beat 3 of the last 8 reports
- Altman Z 4.27 · Piotroski F 3
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 34 | Weak | |
| 34 | Weak | |
| 34 | Weak | |
| 34 | Weak | |
| 34 | Weak | |
| 34 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $135.68 | |
| Change on the day | +1.25% | |
| 52-week range | $123.00–$260.19 | |
| Market capitalisation | $7.14B | — |
| Price / earnings (trailing) | 39.83 | |
| Shares traded on the day | 639.7K | |
| Beta (volatility vs the S&P 500) | 0.6 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · below the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
How to read these dates
Estimated dates can change.
Other perspectives
Council score for Axsome Therapeutics (AXSM): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
2 lenses, 2 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
One of these lenses reads this company more favourably than the MoonshotScore does: Griffin-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Axsome Therapeutics (AXSM), and what does it report?
Short answer · as of
Axsome is no longer simply a clinical-stage biotechnology developer.
Research dated 2026-09-13.
Reported revenue comes from product sales, while its development portfolio seeks additional uses and treatments across central nervous system disorders.
The financial statements therefore capture two businesses at once: a commercial operation building product demand and a research organization funding late-stage programs. Revenue has expanded sharply, but selling and administrative expense now outweighs research spending by a wide margin, making commercial efficiency increasingly important.
What do the latest results show for Axsome Therapeutics (AXSM)?
Short answer · as of
The most recent reported quarter, Q3 FY2025, carried revenue of $171M.
Research dated 2026-09-13.
The latest period brought renewed sequential revenue growth, higher gross profit and narrower operating and net losses. Revenue reached the strongest level in the reported quarterly series after a brief pullback, extending the substantial expansion visible in the annual record.
The improvement was not yet clean. Selling and administrative expense continued to climb, operating cash outflow worsened, and the latest reported revenue and loss both fell short of consensus. Higher gross profit and lower research expense helped the accounting loss narrow despite the heavier commercial cost base.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $259.69M Sep 30, 2026
- Latest quarter · R&D
- $50.62M Sep 30, 2026
- Latest quarter · SG&A
- $203.11M Sep 30, 2026
- Latest quarter · FMP standardized operating result
- −$11.07M Sep 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | $259.69M | $50.62M | $203.11M | −$11.07M |
| Jun 30, 2026 | $218.38M | $46.23M | $208.14M | −$49.65M |
| Mar 31, 2026 | $191.20M | $52.68M | $185.00M | −$63.36M |
| Dec 31, 2025 | $196.00M | $48.79M | $169.30M | −$29.43M |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $259.69M Nov 2, 2026
- Latest report · revenue estimate
- $249.19M Nov 2, 2026
- Latest report · revenue vs estimate
- Above estimate Nov 2, 2026
- Latest report · EPS vs estimate
- Above estimate Nov 2, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Nov 2, 2026 | $259.69M | $249.19M | −$0.2500 | −$0.6342 |
| Aug 10, 2026 | $216.35M | $221.11M | −$0.9900 | −$0.8921 |
| May 4, 2026 | $189.40M | $190.91M | −$1.2600 | −$0.8500 |
| Feb 23, 2026 | $194.69M | $193.36M | −$0.7100 | −$0.7000 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2025 | $171M | -$47M | -$0.94 (diluted) |
| Q4 FY2025 | $196M | -$29M | -$0.56 (diluted) |
| Q1 FY2026 | $191M | -$65M | -$1.26 (diluted) |
| Q2 FY2026 | $218M | -$51M | -$0.99 (diluted) |
What are the financial strengths and risks for Axsome Therapeutics (AXSM)?
Short answer
Cash and short-term investments were $313.86M at the Sep 30, 2026 balance-sheet date. Operating cash flow was −$9.47M for the quarter ended Sep 30, 2026, meaning operations used cash. These figures do not establish a cash runway.
Research dated 2026-09-13.
Liquidity exceeds total debt, leaving Axsome with net cash, and the cash balance has remained within a relatively narrow band across the reported window despite operations consuming cash in most periods. That provides room to fund commercialization and clinical work without an immediate balance-sheet constraint.
The risk sits in the conversion of growth into durable cash generation. Gross margins are high, but selling and administrative spending is rising rapidly, operating losses persist, and the market value stands far above the net cash position. A slowdown in product revenue without a matching adjustment in spending would pressure both the valuation case and the financial cushion.
Data-derived red flags
- Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Rich valuation — a P/E of 39.83 runs well above the Healthcare sector’s ~21.70x, leaving little room for a miss.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- −$9.47M Sep 30, 2026
- Previous quarter · operating cash flow
- −$32.95M Jun 30, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Sep 30, 2026 | −$9.47M | −$200,000 |
| Jun 30, 2026 | −$32.95M | −$450,000 |
| Mar 31, 2026 | −$20.70M | −$120,000 |
| Dec 31, 2025 | −$18.65M | −$70,000 |
How to read these figures
Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.
What should you watch next at Axsome Therapeutics (AXSM)?
Short answer · as of
The next earnings report is expected on Feb 22, 2027.
Research dated 2026-09-13.
The upcoming earnings report needs to be read through three linked observations: whether revenue accelerates as consensus expects, whether the loss contracts, and whether operating cash flow begins to follow the improvement in the income statement. Revenue growth accompanied by another sharp increase in commercial expense would be less persuasive than growth that narrows losses and reduces cash use.
Clinical progress also matters because Axsome’s expansion path reaches beyond current product sales. Updates involving depression, Alzheimer’s disease agitation, smoking cessation, migraine, narcolepsy or fibromyalgia could change the breadth of the future portfolio, while delays would leave more of the burden on the existing commercial business.
What the records here don't tell us
- The newest quarter held here (Q3 FY2025) was filed Nov 3, 2025 — 12 months ago.
Checked against the records this page reads, on the dates shown above.
How does Axsome Therapeutics compare with its peers?
Short answer
Axsome Therapeutics's score ranks 12th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Axsome differs from a pre-revenue biotechnology developer because product sales already form a substantial and rapidly expanding business. It also differs from a mature specialty pharmaceutical company because continuing losses and a broad late-stage central nervous system pipeline still make research execution and financing discipline central to the story.
That combination produces attractive product gross margins but heavy commercial and development spending. Comparable businesses may depend mainly on trial outcomes or mainly on established brands; Axsome must prove that its commercial platform can fund continued portfolio expansion.
| Company | Price | Market value | Score |
|---|---|---|---|
| $93.53 Nov 19, 2026 | $7.35B | 98 5-pillar Nov 18, 2026 | |
| $315.82 Nov 19, 2026 | $9.36B | 96 5-pillar Nov 18, 2026 | |
| $67.79 Nov 18, 2026 | $7.42B | 91 5-pillar Nov 18, 2026 | |
| $64.88 Nov 19, 2026 | $9.81B | 90 5-pillar Nov 18, 2026 | |
| $127.16 Nov 18, 2026 | $8.30B | 88 5-pillar Nov 18, 2026 | |
| $19.50 Nov 18, 2026 | $5.59B | 83 5-pillar Nov 18, 2026 | |
| $298.71 Nov 18, 2026 | $5.98B | 71 5-pillar Nov 18, 2026 | |
| $97.57 Nov 19, 2026 | $6.62B | 67 5-pillar Nov 18, 2026 | |
| $124.39 Nov 19, 2026 | $5.25B | 66 5-pillar Nov 18, 2026 | |
| $156.23 Nov 18, 2026 | $6.35B | 64 5-pillar Nov 18, 2026 | |
| $247.77 Nov 18, 2026 | $15.9B | 40 5-pillar Nov 18, 2026 | |
| Axsome Therapeutics (AXSM) — this page | $135.68 | $7.14B | 34 |
| $43.65 Nov 19, 2026 | $6.17B | 12 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $238.00 – $380.00
- Consensus target
- $279.25
- Median target
- $267.50
Consensus record · Captured .
Measured against a quoted price of $135.68 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 500 records, those within the last 180 days, newest dated Sep 3, 2026
- Transactions
- 38
- Identified insiders
- 7
- Purchases
- 0
- Sales
- 14
- Other transactions
- 24
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 77.7% Period end Sep 30, 2026
- Previous quarter · ownership
- 75.3% Prior to period end Sep 30, 2026
- Reporting holders
- 490 Period end Sep 30, 2026
- Previous quarter · holders
- 542 Prior to period end Sep 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Blackrock, INC. | 3,451,847 |
| Vanguard Capital Management LLC | 2,007,061 |
| Vanguard Portfolio Management LLC | 1,972,645 |
| Invesco Ltd. | 1,930,336 |
| Fmr LLC | 1,444,439 |
Tracked investors
Which of the 16 named investors we follow held AXSM in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Bridgewater Associates | Founded by Ray Dalio | Q3 2026 | 0.10% | $23.20M | Added +116.1% shares |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Axsome Therapeutics (AXSM)?
Axsome Therapeutics Healthcare Stock: Key Questions Answered
Research dated 2026-09-13; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What does Axsome actually sell while its CNS pipeline advances?
Reported revenue comes from product sales, while the company continues developing treatments across several central nervous system disorders. Its results therefore reflect active commercialization alongside clinical research rather than research spending alone.
Why did Axsome’s latest accounting loss narrow as cash use increased?
Higher gross profit and lower research expense more than offset the rise in selling and administrative spending, narrowing the reported loss. Operating cash outflow nevertheless increased, so the income-statement improvement had not yet translated into stronger cash generation.
Can Axsome’s cash position carry its late-stage CNS programs?
Liquidity exceeds debt and cash has been broadly stable across the reported span, providing a meaningful cushion. Operations still consume cash in most periods, so the durability of that cushion depends on product growth eventually producing sustained operating cash.
Which disorders could expand Axsome beyond its current product revenue?
The development portfolio spans depression, treatment-resistant depression, Alzheimer’s disease agitation, smoking cessation, migraine, narcolepsy and fibromyalgia. Progress across those programs could broaden the commercial base beyond the products generating revenue now.
What is the AXSM stock price today?
The last price recorded for Axsome Therapeutics, Inc. (AXSM), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the AXSM price target?
The analyst consensus price target for Axsome Therapeutics, Inc. (AXSM), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 80 figures on this page — 1 from SEC filings and earnings calls, 72 from Financial Modeling Prep (FMP), 3 with no recorded source, 3 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-13), by section of the research
ETFs that hold AXSM
Funds in our ETF coverage that list AXSM among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| iShares Neuroscience and Healthcare ETF (IBRN) | 4.53% |